MA44483A - Procédés pour traiter des événements indésirables gastro-intestinaux d'origine immunitaire dans des traitements oncologiques immunitaires - Google Patents

Procédés pour traiter des événements indésirables gastro-intestinaux d'origine immunitaire dans des traitements oncologiques immunitaires

Info

Publication number
MA44483A
MA44483A MA044483A MA44483A MA44483A MA 44483 A MA44483 A MA 44483A MA 044483 A MA044483 A MA 044483A MA 44483 A MA44483 A MA 44483A MA 44483 A MA44483 A MA 44483A
Authority
MA
Morocco
Prior art keywords
immune
oncological
methods
adverse events
treatments
Prior art date
Application number
MA044483A
Other languages
English (en)
Inventor
Rachael L Brake
Eric H Westin
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of MA44483A publication Critical patent/MA44483A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2845—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA044483A 2016-03-24 2017-03-24 Procédés pour traiter des événements indésirables gastro-intestinaux d'origine immunitaire dans des traitements oncologiques immunitaires MA44483A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662312671P 2016-03-24 2016-03-24

Publications (1)

Publication Number Publication Date
MA44483A true MA44483A (fr) 2019-01-30

Family

ID=58489432

Family Applications (1)

Application Number Title Priority Date Filing Date
MA044483A MA44483A (fr) 2016-03-24 2017-03-24 Procédés pour traiter des événements indésirables gastro-intestinaux d'origine immunitaire dans des traitements oncologiques immunitaires

Country Status (5)

Country Link
US (2) US11760803B2 (fr)
EP (1) EP3433275A1 (fr)
JP (2) JP7069032B2 (fr)
MA (1) MA44483A (fr)
WO (1) WO2017165778A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202408573A (zh) * 2015-11-18 2024-03-01 美商必治妥施貴寶公司 使用抗ｐｄ－１抗體與抗ｃｔｌａ－４抗體之組合以治療肺癌
WO2017218434A1 (fr) 2016-06-12 2017-12-21 Millennium Pharmaceuticals, Inc. Méthode de traitement de maladie intestinale inflammatoire
CA3089704A1 (fr) * 2018-02-02 2019-08-08 Oncoimmune, Inc. Procedes de selection et de conception d'anticorps anti-ctla-4 plus surs et plus efficaces pour la therapie du cancer
GB201913988D0 (en) * 2019-09-27 2019-11-13 Celleron Therapeutics Ltd Novel treatment
EP4359795A1 (fr) * 2021-06-21 2024-05-01 Institut Gustave-Roussy Méthodes de diagnostic d'une dysbiose induite par un cancer ou des antibiotiques et leur utilisation pour améliorer le traitement du cancer par immunothérapie

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US748802A (en) 1904-01-05 Territory
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
JP3095168B2 (ja) 1988-02-05 2000-10-03 エル． モリソン，シェリー ドメイン‐変性不変部を有する抗体
EP2192131A1 (fr) 1992-08-21 2010-06-02 Vrije Universiteit Brussel Immunoglobulines dépourvus de chaînes légères
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
US6838254B1 (en) 1993-04-29 2005-01-04 Conopco, Inc. Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of camelidae
EP0714409A1 (fr) 1993-06-16 1996-06-05 Celltech Therapeutics Limited Anticorps
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
DK0808367T3 (da) 1995-02-10 2007-11-05 Millennium Pharm Inc Vaskulære slimhindeaddressiner samt anvendelse deraf
US7803904B2 (en) 1995-09-01 2010-09-28 Millennium Pharmaceuticals, Inc. Mucosal vascular addressing and uses thereof
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
US6261804B1 (en) 1997-01-21 2001-07-17 The General Hospital Corporation Selection of proteins using RNA-protein fusions
WO1998031700A1 (fr) 1997-01-21 1998-07-23 The General Hospital Corporation Selection de proteines a l'aide de fusions arn-proteine
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
US6984720B1 (en) 1999-08-24 2006-01-10 Medarex, Inc. Human CTLA-4 antibodies
JP2003520828A (ja) 2000-01-27 2003-07-08 ジェネティクス インスティテュート，エルエルシー Ｃｔｌａ４（ｃｄ１５２）に対する抗体、これを含む結合体、およびその使用
US20010046496A1 (en) 2000-04-14 2001-11-29 Brettman Lee R. Method of administering an antibody
IL149701A0 (en) 2001-05-23 2002-11-10 Pfizer Prod Inc Use of anti-ctla-4 antibodies
AU2001298053A1 (en) 2001-09-27 2003-04-14 Pieris Proteolab Ag Muteins of apolipoprotein D
IL149820A0 (en) 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
CN101899114A (zh) 2002-12-23 2010-12-01 惠氏公司 抗pd-1抗体及其用途
US7322582B2 (en) 2003-07-17 2008-01-29 Mind Wurx, Llc Enhanced shopping cart with lowered center of gravity and frame therefor
GB0400440D0 (en) 2004-01-09 2004-02-11 Isis Innovation Receptor modulators
PE20051053A1 (es) 2004-01-09 2005-12-12 Pfizer ANTICUERPOS CONTRA MAdCAM
CN101124248A (zh) 2004-08-11 2008-02-13 特鲁比昂药品公司 结合域融合蛋白
CN103304667B (zh) 2004-09-03 2015-04-08 健泰科生物技术公司 人源化的抗-β7拮抗剂及其应用
EP1793858A4 (fr) 2004-09-08 2008-12-10 Univ Ohio State Res Found Anticorps monoclonaux humains anti-ctla4 dans le traitement du cancer
CN117534755A (zh) 2005-05-09 2024-02-09 小野药品工业株式会社 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法
KR101888321B1 (ko) 2005-07-01 2018-08-13 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
US20070122404A1 (en) 2005-11-17 2007-05-31 O'keefe Theresa L Humanized immunoglobulin reactive with alpha4beta7 integrin
CN101325971A (zh) 2005-12-07 2008-12-17 米德列斯公司 Ctla-4抗体剂量递增方案
EP2007808A4 (fr) 2006-04-14 2010-07-21 Trubion Pharmaceuticals Inc Protéines de liaison comportant une charnière d'immunoglobulines et des régions fc ayant des fonctions effectrices altérées
NZ600758A (en) 2007-06-18 2013-09-27 Merck Sharp & Dohme Antibodies to human programmed death receptor pd-1
TWI444379B (zh) 2007-06-29 2014-07-11 Sunesis Pharmaceuticals Inc 有用於作為Ｒａｆ激酶抑制劑之化合物
US20100330093A1 (en) 2007-12-12 2010-12-30 Sciclone Pharmaceuticals, Inc. Treatment of melanoma with alpha thymosin peptides in combination with antibodies against cytotoxic t lymphocyte-associated antigen 4 (ctla4)
EP2240204A1 (fr) 2008-02-04 2010-10-20 Medarex, Inc. Anticorps anti-clta-4 avec blocage réduit de la liaison de ctla-4 à b7 et leurs utilisations
US8119129B2 (en) 2008-08-01 2012-02-21 Bristol-Myers Squibb Company Combination of anti-CTLA4 antibody with dasatinib for the treatment of proliferative diseases
US7993640B2 (en) 2008-08-06 2011-08-09 Light Sciences Oncology, Inc. Enhancement of light activated therapy by immune augmentation using anti-CTLA-4 antibody
JP2012510429A (ja) 2008-08-25 2012-05-10 アンプリミューン、インコーポレーテッド Ｐｄ−１アンタゴニストおよびその使用方法
JP5794917B2 (ja) 2008-09-12 2015-10-14 アイシス・イノベーション・リミテッドＩｓｉｓ Ｉｎｎｏｖａｔｉｏｎｌｉｍｉｔｅｄ Ｐｄ−１特異抗体およびその使用
US8927697B2 (en) 2008-09-12 2015-01-06 Isis Innovation Limited PD-1 specific antibodies and uses thereof
US8552154B2 (en) 2008-09-26 2013-10-08 Emory University Anti-PD-L1 antibodies and uses therefor
WO2010042433A1 (fr) 2008-10-06 2010-04-15 Bristol-Myers Squibb Company Combinaison d'anticorps cd137 et d'anticorps ctla-4 pour le traitement de maladies prolifératives
JO3101B1 (ar) 2008-12-02 2017-09-20 Takeda Pharmaceuticals Co مشتقات بنزوثيازول كعوامل مضادة للسرطان
CN102245640B (zh) 2008-12-09 2014-12-31 霍夫曼-拉罗奇有限公司 抗-pd-l1抗体及它们用于增强t细胞功能的用途
GB0903325D0 (en) 2009-02-26 2009-04-08 Univ Aberdeen Antibody molecules
WO2010107752A2 (fr) 2009-03-20 2010-09-23 Amgen Inc. Anticorps antagoniste spécifique d'un hétérodimère alpha-4-bêta-7
US20130017199A1 (en) 2009-11-24 2013-01-17 AMPLIMMUNE ,Inc. a corporation Simultaneous inhibition of pd-l1/pd-l2
WO2011110604A1 (fr) 2010-03-11 2011-09-15 Ucb Pharma, S.A. Anticorps pd-1
TW201134488A (en) 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
WO2011130434A2 (fr) 2010-04-13 2011-10-20 Celldex Therapeutics Inc. Anticorps qui se lient au cd27 humain et utilisations de ceux-ci
WO2012027536A1 (fr) 2010-08-26 2012-03-01 Bristol-Myers Squibb Company Combinaison d'anticorps anti-ctla4 avec des inhibiteurs de braf pour le traitement synergique de maladies prolifératives
GB201103955D0 (en) 2011-03-09 2011-04-20 Antitope Ltd Antibodies
EP2699264B1 (fr) 2011-04-20 2018-03-14 Medlmmune, LLC Anticorps et autres molécules qui se lient à b7-h1 et à pd-1
EP2704742B1 (fr) 2011-05-02 2017-07-12 Millennium Pharmaceuticals, Inc. Formulation pour un anticorps anti- 4 7
UA116189C2 (uk) * 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
WO2013019620A2 (fr) 2011-07-29 2013-02-07 Glaxosmithkline Llc Méthode de traitement du cancer au moyen d'une combinaison contenant un inhibiteur de braf, un inhibiteur de mek et un anticorps anti-ctla-4
TW202114735A (zh) 2011-08-01 2021-04-16 美商建南德克公司 利用pd-1軸結合拮抗劑及mek抑制劑治療癌症之方法
WO2013142796A2 (fr) 2012-03-23 2013-09-26 Bristol-Myers Squibb Company Procédés de traitements au moyen d'anticorps anti-ctla4
WO2014066532A1 (fr) 2012-10-23 2014-05-01 Bristol-Myers Squibb Company Association d'anticorps anti-kir et anti-ctla-4 pour le traitement du cancer
US20140323533A1 (en) 2013-04-29 2014-10-30 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with tubulin modulating agents for the treatment of proliferative diseases
SI3702373T1 (sl) 2013-09-13 2022-11-30 Beigene Switzerland Gmbh Protitelesa proti PD-1 in njihova uporaba kot terapevtiki in diagnostiki
MX2016004736A (es) 2013-10-18 2016-07-26 Regeneron Pharma Metodos y composiciones que comprenden una combinacion de un antagonista de vegf y un anticuerpo anti-ctla-4.
RS61661B1 (sr) 2014-02-21 2021-04-29 Nektar Therapeutics India Pvt Ltd Il-2rbeta-selektivni agonisti u kombinaciji sa anti-ctla-4 antitelom ili anti-pd-1 antitelom
UY36046A (es) 2014-03-26 2015-10-30 Millennium Pharm Inc Formulaciones farmacéuticas, procesos para la preparación y métodos de uso
KR20220162844A (ko) 2014-05-13 2022-12-08 메디뮨 리미티드 비-소세포 폐암을 치료하기 위한 항-ｂ7-ｈ1 및 항-ｃｔｌａ-4 항체
CN105296433B (zh) 2014-08-01 2018-02-09 中山康方生物医药有限公司 一种ctla4抗体、其药物组合物及其用途
EP3012270A1 (fr) 2014-10-23 2016-04-27 Institut Gustave Roussy Produits pour moduler la composition microbienne afin d'améliorer l'efficacité d'un traitement du cancer avec un bloqueur de vérification immunitaire
JP2017537105A (ja) 2014-11-26 2017-12-14 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 瘻孔を伴うクローン病の治療用ベドリズマブ
WO2016105572A1 (fr) 2014-12-24 2016-06-30 Millennium Pharmaceuticals, Inc. Prévision du résultat de traitement avec un anticorps dirigé contre l'intégrine anti-α4β7

Also Published As

Publication number Publication date
JP2022105157A (ja) 2022-07-12
US20190040140A1 (en) 2019-02-07
WO2017165778A1 (fr) 2017-09-28
US20240247067A1 (en) 2024-07-25
JP2019512523A (ja) 2019-05-16
JP7069032B2 (ja) 2022-05-17
EP3433275A1 (fr) 2019-01-30
JP7560508B2 (ja) 2024-10-02
US11760803B2 (en) 2023-09-19

Similar Documents

Publication Publication Date Title
MA44483A (fr) Procédés pour traiter des événements indésirables gastro-intestinaux d'origine immunitaire dans des traitements oncologiques immunitaires
DK3459597T3 (da) Enkeltdomæne-antistof mod ctla4 og deraf afledt protein
MA43283A (fr) Procédés et compositions pour le traitement du cancer
MA43135A (fr) Compositions et méthodes pour le du traitement du cancer
MA51306A (fr) Compositions et procédés améliorés pour le traitement du déficit en ornithine transcarbamylase
MA41119A (fr) Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique
MA42135A (fr) Méthodes et trousses pour traiter la dépression
MA39722A (fr) Composition pour son utilisation dans une methode de traitement ou de prevention de l'anemie par l'inhibition de l'activine b et du gdf11
MA51074A (fr) Procédés et compositions pour traiter des troubles à l'aide de polypeptides de follistatine
MA41863A (fr) Compositions et procédés permettant de traiter une anémie
MA45675A (fr) Méthodes et compositions permettant le traitement du cancer
MA45208A (fr) Procédé d'identification de l'étendue du vieillissement dans un asphalte
DE112017003584T8 (de) Vorrichtung und verfahren zur verbesserung des gütefaktorverminderungsverlusts und des phasengleichgewichts in abschwächerschaltkreisen
IL265750B (en) Activators of autophagic flux and phospholipase d and clearance of protein aggregates including tau and treatment of proteinopathies
MA52150A (fr) Compositions et procédés faisant intervenir des molécules probiotiques
MA46842A (fr) Méthodes de traitement de l'obésité au moyen d'anticorps anti-angptl8
DE102012100553A8 (de) Verfahren und Vorrichtung zum Spleißen von Garn
DE112015000850A5 (de) Verfahren zur Herstellung von Halbleiterbauelementen und Halbleiterbauelement
DE102014119391B8 (de) Vorrichtung und Verfahren zum Etikettieren von einzelnen Packungen
MA45674A (fr) Méthodes et matériaux permettant d'évaluer une réponse à des traitements de déplétion de plasmoblastes et de plasmocytes
MA45848A (fr) Cobicistat destiné à être utilisé dans des traitements du cancer
DE112017005966A5 (de) Messgerät und Verfahren zum Betreiben des Messgeräts
DE112015004389A5 (de) Vorrichtung zum Entfernen der Äste von lebenden Bäumen
DK3365329T3 (da) Nurr1:rxr aktiverende forbindelser til samtidig behandling af symptomer og patologi for parkinsons sygge
MA46542A (fr) Procédés et compositions pour une immunothérapie par tusc2